

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 24, 2025**

BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	001-38659 (Commission File Number)	26-433375 (IRS Employer Identification No.)
--	---	--

12424 Wilshire Blvd, Ste 745 Los Angeles, California (Address of principal executive offices)	90025 (Zip Code)
---	----------------------------

(203) 409-5444
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value \$0.001 per share	BSGM	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On March 24, 2025, BioSig Technologies, Inc. (the "Company") was notified by the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has successfully met the qualifications to regain full compliance for continued listing on the Nasdaq Capital Market.

As previously disclosed on March 5, 2025, the Company had been notified on October 18, 2024 by Nasdaq that the Nasdaq Listing and Hearing Review Council had granted the Company an exception through March 7, 2025 to evidence compliance with Nasdaq Listing Rule 5550(b), namely either the \$35 million in market value of listed securities requirement or the alternative requirement of \$2.5 million in stockholders' equity (the "Equity Rule") for continued listing on the Nasdaq Capital Market. On March 6, 2025, the Company submitted documents to Nasdaq evidencing its compliance with the Equity Rule and had awaited Nasdaq's formal confirmation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSIG TECHNOLOGIES, INC.

Date: March 25, 2025

By: /s/ Anthony Amato
Name: Anthony Amato
Title: Chief Executive Officer
